New York, October 22, 2024 - PRISM MarketView - Annexon, Inc. (Nasdaq: ANNX) presented new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology (AAO) 2024 meeting. The data demonstrated enhanced protection of vision and greater preservation of central photoreceptor cells in patients with less advanced GA.
Key Highlights:
- Enhanced Vision Protection: Patients with less advanced disease saw greater protection from vision loss, with 0% of patients treated with ANX007 losing 15 letters of vision compared to 17% of sham patients.
- Photoreceptor Protection: ANX007 significantly reduced the loss of photoreceptors in patients with more intact vision at baseline, showing up to a 61% reduction in photoreceptor damage.
- Phase 3 Trial Timeline: Pivotal Phase 3 ARCHER II data are expected in the second half of 2026.
“We are further encouraged by ANX007’s more pronounced treatment effect on both preservation of vision and photoreceptors in patients with less advanced disease. Importantly, these Phase 2 data highlight the potential of ANX007 to deliver a differentiated benefit, particularly with earlier intervention in a neurodegenerative disease, and we are encouraged by the promise ANX007 holds to help millions of patients worldwide with dry AMD and GA.”
Douglas Love, President and CEO of Annexon
ANX007 is a first-in-class treatment designed to block C1q locally in the eye, preventing neurodegeneration and preserving vision in dry AMD patients.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities